NEUCHÂTEL, Switzerland--(BUSINESS WIRE)--Apr. 21, 2016--
Masimo (NASDAQ:
MASI) announced today that Centre Hospitalier Universitaire (CHU) de
Limoges, in Limoges, France has installed Masimo’s Radical-7®,
including noninvasive, continuous hemoglobin (SpHb®), Pleth
Variability Index (PVI®), and SET® pulse oximetry
technology, to monitor surgical patients and critical patients in the
post-anesthesia care unit and intensive care unit.
“For three years, we tested SpHb and PVI on every surgical patient in
our facility and then compared this data to the previous period without
this technology,” said Professor Nathalie Nathan, Head of the Department
of Anesthesiology at CHU Limoges. “In this retrospective review of
before and after periods across the entire hospital, in different
clinical settings and with many different practitioners, we found that
there was a notable reduction in mortality in surgeries lasting longer
than 2 hours and patients in the 60+ age range.”
SpHb is a breakthrough measurement that noninvasively and continuously
measures total hemoglobin in the blood, and offers real-time visibility
into changes – or lack of changes – in hemoglobin between invasive blood
samples. PVI is a measure of dynamic changes in Perfusion Index (PI)
that occur during one or more complete respiratory cycles, and may show
changes that reflect physiologic factors such as vascular tone,
circulating blood volume, and intrathoracic pressure excursions. PVI is
noninvasive, easily obtained and has no incremental procedural cost.
“According to the World Health Organization, France ranks number one in
the world in patient safety. For over 40 years, CHU Limoges has been
recognized as a leading hospital in France for patient care, training,
research and innovation,” stated Joe Kiani, Founder and CEO of Masimo.
“We are impressed with the format of this three-year evaluation and
happy to see Limoges incorporate SpHb and PVI in the care of their
patients.”
CHU Limoges is a university hospital that includes four locations and
one nursing home. Dupuytren (866 beds) hosts an emergency department,
Jean Rebeyrol (459 beds) handles rehabilitation patients, Cluzeau (59
beds) specializes in respiratory diseases, diabetes, endocrinology and
metabolic diseases, and Mother & Child (197 beds) specializes in
pediatric and gynecological emergencies and has 197 beds.
@MasimoInnovates
| #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated to be used
on more than 100 million patients in leading hospitals and other
healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive and
continuous monitoring of blood constituents that previously could only
be measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and
more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index
(ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In
2014, Masimo introduced Root®, an intuitive patient monitoring and
connectivity platform with the Masimo Open Connect (MOC-9) interface.
Masimo is also taking an active leadership role in mHealth with products
such as the Radius-7™ wearable patient monitor and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo’s SpHb®, PVI®, and SET® technologies. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo’s SpHb®, PVI®, and SET®
technologies, contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions with comparable accuracy
and unique advantages, including: immediate and continuous results that
enable earlier treatment without causing invasive trauma in all patients
and in every clinical situation; as well as other factors discussed in
the "Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160421005279/en/
Source: Masimo
Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com